JNJ-79032421 (Johnson & Johnson)

JNJ-79032421 (Johnson & Johnson): sourced facts only. name: "Crystal structure analysis confirmed JNJ-79032421 binding to the membrane-restricted, non-shed C-terminal region of MSLN." [PMID:41773493]; target: "Crystal structure analysis confirmed JNJ-79032421 binding to the membrane-restricted, non-shed C-terminal region of MSLN." [PMID:41773493]; developer: "Oncology, Johnson & Johnson, Beerse, Belgium." [PMID:41773493]; modality: "We describe JNJ-79032421, a bispecific antibody (BsAb) targeting cluster of differentiation (CD) 3 on T cells and the membrane-restricted, non-shed region of full-length MSLN on cancer cells." [PMID:41773493]; stage: "In cancer cell lines and cell line-derived and patient-derived xenograft mouse models, increasing levels of MSLN expression led to increased JNJ-79032421 potency." [PMID:41773493]